Patients receiving CAR-T cell therapy often report brain fog, and new research shows this cognitive impairment stems from the therapy itself, not just the cancer or other treatments. A mouse study revealed that CAR-T-induced immune responses activate brain microglia, triggering inflammation that damages myelin-producing cells, reducing signal efficiency in the brain.
